Treatment-Induced BAFF Expression and B Cell Biology in Multiple Sclerosis

Treatment-Induced BAFF Expression and B Cell Biology in Multiple Sclerosis

Although fingolimod and interferon-β are two mechanistically different multiple sclerosis (MS) treatments, they both induce B cell activating factor (BAFF) and shift the B cell pool towards a regulatory phenotype. However, whether there is a shared mechanism between both treatments in how they influ...

Full description

Bibliographic Details
Main Authors: Ide Smets, Teresa Prezzemolo, Maya Imbrechts, Klara Mallants, Tania Mitera, Stéphanie Humblet-Baron, Bénédicte Dubois, Patrick Matthys, Adrian Liston, An Goris
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
B cells
B cell activating factor (BAFF)
fingolimod
Interferon-β
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.676619/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.676619/full

Similar Items